Meeting
2011 ASCO Annual Meeting
Bone effects of adjuvant tamoxifen (T), letrozole (L), or L plus zoledronic acid (Z) in early breast cancer (EBC): The phase III HOBOE study.
Authors
F. Perrone
National Cancer Institute, Napoli, Italy
F. Perrone , C. Gallo , S. Lastoria , F. Nuzzo , A. Gravina , G. Landi , E. Rossi , C. Pacilio , V. Labonia , F. Di Rella , M. De Laurentiis , M. C. Piccirillo , M. Di Maio , P. Giordano , G. Daniele , G. De Feo , R. Fiore , S. Signoriello , G. Esposito , A. de Matteis
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Breast Cancer - HER2/ER
Track
Breast Cancer
Sub Track
ER+
Clinical Trial Registration Number
NCT00412022
Citation
J Clin Oncol 29: 2011 (suppl; abstr 517)
Abstract #
517
Poster Bd #
6
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Estrogen levels in premenopausal (prem) patients (pts) with hormone-receptor positive (HR+) early breast cancer (BC) receiving adjuvant triptorelin (Trip) plus exemestane (E) or tamoxifen (T) in the SOFT trial: SOFT-EST substudy.
First Author: Meritxell Bellet
Poster
2021 ASCO Annual Meeting
Final analysis of the PROMISE-GIM6 phase III trial assessing GnRH agonist use during chemotherapy as a strategy to preserve ovarian function in premenopausal patients with early breast cancer.
First Author: Matteo Lambertini
Poster
2023 ASCO Breakthrough
Delayed versus immediate use of zoledronic acid for postmenopausal patients with ER/PR positive early breast cancer who are using adjuvant letrozole.
First Author: Mai Abdel Gelil
Poster
2022 ASCO Annual Meeting
Estradiol (E2) levels in premenopausal women with hormone receptor-positive (HR+) breast cancer (BC) on ovarian function suppression (OFS) with gonadotropin-releasing hormone agonists (GnRHa).
First Author: Megan Elizabeth Tesch